TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03340376
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: atezolizumab
Study: NCT01058668
Drug: Cariprazine
Normalized name: Cariprazine
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for three weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
Study: NCT00640328
Drug: Ofatumumab 100
Normalized name: ofatumumab 100 MG in 5 ML Injection
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg
Study: NCT00640328
Drug: Ofatumumab 300
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300mg
Study: NCT00640328
Drug: Ofatumumab 700
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 700mg
Study: NCT03461328
Drug: Magnesium Sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intra-operative infusion of of 10% MgSO2 , stating by a laoding dose of 30be used, a loading dose of 30 mg/kg over 20 min followed by continuous infusion of 10 mg/kg/hr accomplish the total laryngectomy.
Study: NCT00252967
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg of Atorvastatin
Study: NCT04322292
Drug: C-CAR088
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+T cells/kg.~Divided into three dose ranges of low(1.0-3.0×10\^6 CAR+T cells/kg),medium(3.0-6.0×10\^6 CAR+T cells/kg) and high(6.0-9.0×10\^6 CAR+T cells/kg).~Other Name: CBM.BCMA Chimeric Antigen Receptor T cell.
Study: NCT02092363
Drug: OMP-54F28, Paclitaxel and Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04550702
Drug: Mirabegron 25mg
Normalized name: MIRABEGRON 25MG SA TAB
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron 25 mg per day
Study: NCT00445796
Drug: Artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00445796
Drug: Amodiaquine
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01251107
Drug: Bleomycin
Normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m2 IV day 8 during cycles 1 to 8
Study: NCT01251107
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m2 iv on days 1 to 3 during cycles 1 to 4; 100 mg/m2 iv on days 1 to 3 during cycles 5 to 8
Study: NCT01251107
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4 mg/m2 iv (max 2 mg) on day 8 during cycles 1 to 8
Study: NCT01251107
Drug: Procarbazine
Normalized name: Procarbazine
DrugBank: Procarbazine (DB01168)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m2 po from day 1 to 7 during cycles 1 to 8
Study: NCT01251107
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/m2 po from day 1 to 14 during cycles 1 to 8
Study: NCT01251107
Drug: Bleomycin
Normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m2 iv on days 1 and 15 in each cycle
Study: NCT01251107
Drug: Vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 mg/m2 iv on days 1 and 15 in each cycle
Study: NCT01251107
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 375 mg/m2 iv on days 1 and 15 in each cycle
Study: NCT00137111
Drug: Prednisone, Dexamethasone, Vincristine, Daunorubicin
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See Detailed Description sections for details on treatment interventions.
Study: NCT01160666
Drug: Belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab will be administered at 10 mg/kg at Days 0, 14, 28 and then every 28 days until week 24 for all patients and week 48 for those considered responders at week 28.
Study: NCT03115567
Drug: Triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 weeks of twice daily application of 0.1% triamcinolone cream to the face, chest, and back.
Study: NCT03269045
Drug: ORL-1B
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ORL-1B
Study: NCT02526004
Drug: Ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01326546
Drug: entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg,per day,oral intake.
Study: NCT01868984
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel solution treatment of each lesion encountered will be attempted until the 20 mg Paclitaxel dose limit is met. The volume administered will depend on the diameter and length of the venous outflow segment.
Study: NCT00350142
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly Gemcitabine will be administered at 1000mg/m2 over 100 minutes
Study: NCT00572637
Drug: CEP-18770
Normalized name: CEP-9722
DrugBank: CEP-9722 (DB14882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as intravenous infusion on days 1, 4, 8, and 11 of a 21-day cycle up to 6 cycles. Starting dose 0,1 mg/sqm
Study: NCT00714649
Drug: cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 250mg/m²/week IV before surgery till surgery
Study: NCT01743911
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil pills: 20mg orally, once a day for 2 weeks.
Study: NCT02312635
Drug: D-Cycloserine
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half of the participants will be randomly chosen to receive the medication D-cycloserine in addition to the working memory program, while the other group will receive an inactive pill (placebo).
Study: NCT04999176
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be submitted to an initial screening evaluation during hospitalization. At discharge, they will be randomized and enrolled to be treated with oral rivaroxaban (10 mg once daily, for 30 days), once randomized to this group. A mandatory lower limb Doppler ultrasound will be carried out on day 30±4 as part of the primary efficacy endpoint. A final follow-up phone call visit will be performed on day 60 postoperative.
Study: NCT02022254
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will initiate treatment with 0.25 mg for the first four weeks followed by dose doubling every four weeks up to a dose of 1.0 mg.
Study: NCT04999176
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be submitted to an initial screening evaluation during hospitalization. At discharge, they will be randomized and enrolled to be treated with subcutaneous enoxaparin (40 mg once daily, for 30 days), once randomized to this group. A mandatory lower limb Doppler ultrasound will be carried out on day 30±4 as part of the primary efficacy endpoint. A final follow-up phone call visit will be performed on day 60 postoperative.
Study: NCT02872207
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 uL in other eye
Study: NCT01874054
Drug: brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.8 mg/kg every 3 weeks by intravenous (IV) infusion
Study: NCT01874054
Drug: bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 90 mg/m2 on Days 1 and 2 of 3-week cycles
Study: NCT00820521
Drug: active
Normalized name: Active
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02022254
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: For oral administration twice daily, in two periods, each of 3.5 days duration. The first period is initiated before semaglutide treatment and the second period is initiated at the end of semaglutide treatment.
Study: NCT00003331
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04312048
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to copper IUD insertion
Study: NCT02022254
Drug: warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For oral administration, given as a single dose. The first dose is given before semaglutide treatment and the second dose is given at the end of semaglutide treatment.
Study: NCT01187953
Drug: Prograf (tacrolimus)
Normalized name: tacrolimus Injection [Prograf]
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered per current product labeling
Study: NCT01187953
Drug: LCP-Tacro
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus, once-per-day The initial dose of 0.17 mg/kg will be administered orally in the morning (before noon) within 24 hours following transplantation. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels.
Study: NCT03861559
Drug: mometasone furoate nasal spray
Normalized name: mometasone furoate Nasal Spray
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal administration
Study: NCT00702923
Drug: Bicalutamide and CP-675,206 (Tremelimumab)
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose level -1 :~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 3 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)
Study: NCT01689298
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
Study: NCT01689298
Drug: Carbetocin
Normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
Study: NCT00782951
Drug: Org 28611
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single IV dose of Org 28611 3 mcg/kg after dental impaction surgery
Study: NCT00782951
Drug: morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single IV dose of morphine sulfate 0.12 mg/kg after dental impaction surgery
Study: NCT01292642
Drug: Nicotine Replacement Therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. 21 mg patch for 6 weeks, 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks~2. 14 m g patch for 8 weeks, then 7 mg patch for 2 weeks
Study: NCT00702923
Drug: Bicalutamide, CP-675,206 (tremelimumab)
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose level 1:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 6 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)
Study: NCT00702923
Drug: Bicalutamide, CP-675,206 (Tremelimumab)
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose level 2:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 10 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)
Study: NCT00702923
Drug: Bicalutamide, CP-675,206 (Tremelimumab)
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose level 3:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 15 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)
Study: NCT00702923
Drug: Bicalutamide, CP-675,206
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Final Dose Level:~Bicalutamide 150 mg p.o. q.d. day 1-28, day 85-112~At month 9, if evidence of PSA progression:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 (MTD dose) I.V. over 1 hour, day 29
Study: NCT00115609
Drug: efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800mg for patients treated by rifampicine 600mg for other patients
Study: NCT00115609
Drug: tenofovir DF
Normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300mg once a day
Study: NCT00115609
Drug: emtricitabine
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: one pill of 200mg once a day
Study: NCT04155749
Drug: anitocabtagene-autoleucel
Normalized name: Brexucabtagene autoleucel
DrugBank: Anitocabtagene autoleucel (DB18881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric Antigen Receptor T cells
Study: NCT00605423
Drug: Fluocinolone Acetonide/Medidur
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2 ug/day implant
Study: NCT00605423
Drug: Fluocinolone Acetonide/Medidur
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 ug/day implant
Study: NCT00633659
Drug: Hemospan (MP4OX)
Normalized name: Aerospan
DrugBank: MP4 (DB05313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL of Hemospan (MP4OX)
Study: NCT00633659
Drug: Voluven (HES 130/0.4)
Normalized name: hydroxyethyl starch 130-0.4 Injection [Voluven]
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL of Voluven (HES 130/0.4) solution
Study: NCT04106700
Drug: Apixaban 2.5 MG
Normalized name: apixaban 2.5 MG
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban will be started simultaneously with anti myeloma treatment on day 1 of cycle 1 of VTD, and continues for 4 to 6 months depending on the number of induction cycles administered to the patient
Study: NCT00586261
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone 30 mg daily for 6 months
Study: NCT00586261
Drug: Nitroglycerin
Normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg sublingual nitroglycerin tablet was given to all patients without a contraindication to check the brachial reactivity.
Study: NCT03762759
Drug: Fluciclovine F18
Normalized name: FLUCICLOVINE F18 (9-221 MCI/ML) INJ
DrugBank: Fluciclovine (18F) (DB13146)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03339661
Drug: Group 2A_Proph treatment and γδ T cell expansion
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, γδ T cell expansion will not be detected, so secondary prophylaxis will be initiated in continue during 3 months maximum. The occurrence of γδ T cells expansion during or at the end of secondary prophylaxis will define the group 2A.
Study: NCT03339661
Drug: Group 2B_Proph treatment and no γδ T cell expansion
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, γδ T cell expansion will not be detected, so secondary prophylaxis will be initiated in continue during 3 months maximum. Patients who still not had γδ T cells expansion during or at the end of secondary prophylaxis will compose the group 2B.
Study: NCT01663233
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine will use tablets available at a strength of 5 mg. Patients will be instructed to take the prescribed medication once a day.
Study: NCT02321098
Drug: Loceryl NL + Cosmetic varnish
Normalized name: Botox Cosmetic
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Loceryl NL + Cosmetic varnish once/week for 12 weeks
Study: NCT02321098
Drug: Loceryl NL 15 months
Normalized name: Loceryl
DrugBank: Amorolfine (DB09056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loceryl once/week for additional 15 months
Study: NCT00007605
Drug: Amiodarone
Normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients assigned will receive 400 mg bid for 14 days, 400 mg QAM and 200 mg QHS for 14 days, 300 mg qd for 48 weeks, then 200 mg qd.
Study: NCT00007605
Drug: Sotalol
Normalized name: Sotalol
DrugBank: Sotalol (DB00489)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients assigned will receive 80 mg bid for 7 days and 160 mg bid thereafter.
Study: NCT03610061
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing.
Study: NCT02222207
Drug: Regorafenib, ophthalmic oily suspension (BAY73-4506)
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects receive Regorafenib as eye drops
Study: NCT02222207
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects receive Ranibizumab as intravitreal injection
Study: NCT03976037
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women randomized to either vaginal or buccal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of vaginal or buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.~vaginal or Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated.
Study: NCT00848861
Drug: propofol (sedation for outpatient colonoscopy)
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00848861
Drug: midazolam plus meperidine (sedation for outpatient colonoscopy)
DrugBank: Meperidine (DB00454)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01114503
Drug: Otelixizumab - low dose
Normalized name: ethinyl estradiol
DrugBank: Otelixizumab (DB05496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 day dose rising intravenous infusions of a low dose of otelixizumab
Study: NCT01114503
Drug: Otelixizumab - medium low dose
Normalized name: Medium-Chain Triglycerides
DrugBank: Otelixizumab (DB05496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 day dose rising intravenous infusions of a medium low dose of otelixizumab
Study: NCT01114503
Drug: Otelixizumab - medium high dose
Normalized name: high-density polyethylene
DrugBank: Otelixizumab (DB05496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 day dose rising intravenous infusions of a medium high dose of otelixizumab
Study: NCT01114503
Drug: Otelixizumab - high dose
Normalized name: high-density polyethylene
DrugBank: Otelixizumab (DB05496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 day dose rising intravenous infusions of a high dose of otelixizumab
Study: NCT01114503
Drug: Otelixizumab
Normalized name: Otelixizumab
DrugBank: Otelixizumab (DB05496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 day dose rising intravenous infusions of otelixizumab administered at a dose decided upon results from Part A.
Study: NCT01114503
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly intravenous infusions of methylprednisolone administered as 500 mg per week for 6 weeks and then 250 mg per week for 6 weeks
Study: NCT00622648
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg once daily for 6 to 14 days (10 ± 4 days)
Study: NCT03108313
Drug: aloe vera toothpaste
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: herbal toothpaste used to decrease salivary streptococcus bacterial count
Study: NCT03108313
Drug: fluoride toothpaste
Normalized name: sodium fluoride Toothpaste
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemical toothpaste used to decrease salivary streptococcus bacterial count
Study: NCT02187471
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin capsule for oral use; 75 mg capsule for one week, then 150 mg capsule
Study: NCT00004231
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004231
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004231
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004231
Drug: teniposide
Normalized name: Teniposide
DrugBank: Teniposide (DB00444)
Approvals — FDA: yes, EMA: no, PMDA: no